Sheeran Josette 4

What Happened

• Josette Sheeran, a director of Cyabra, Inc. (CYAB), received a grant reported as an award/acquisition of 144,387 derivative securities on 2026-03-27. The filing shows no exercise price or immediate cash value (price reported as N/A), indicating these are option-type replacement awards rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-27; Form 4 filed: 2026-03-31 (filed on time).
• Amount: 144,387 derivative shares (Replacement Options); price/value: N/A in filing.
• Shares owned after transaction: not specified in the Form 4.
• Footnotes:
  • F1: These Replacement Options vest over three years starting December 14, 2024 — 16.7% vested after 6 months, then 1/12 of the options vest each subsequent quarter, fully vested by the third anniversary of the Vesting Commencement Date.
  • F2/F3: The awards were issued as Replacement Options in connection with the issuer’s business combination with Trailblazer Merger Corporation I; pre‑combination Cyabra options (for an aggregate of 40,000 ordinary shares) were cancelled and replaced on substantially the same terms.

Context

• These are derivative option awards (not exercises or stock sales), so no immediate proceeds or open‑market buying/selling occurred. Option grants to directors are common and typically structured to vest over time to align incentives; they do not by themselves signal a near‑term change in holdings unless subsequently exercised or sold.